Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This makes it the first interchangeable version of NovoLog in the U.S., expanding Biocon’s insulin portfolio amid a growing diabetes burden in the country.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets